Logo image of RCUS

ARCUS BIOSCIENCES INC (RCUS) Stock Fundamental Analysis

NYSE:RCUS - New York Stock Exchange, Inc. - US03969F1093 - Common Stock - Currency: USD

11.07  +0.33 (+3.07%)

After market: 11.2 +0.13 (+1.17%)

Fundamental Rating

3

RCUS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While RCUS seems to be doing ok healthwise, there are quite some concerns on its profitability. RCUS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RCUS has reported negative net income.
In the past year RCUS has reported a negative cash flow from operations.
In the past 5 years RCUS reported 4 times negative net income.
In multiple years RCUS reported negative operating cash flow during the last 5 years.
RCUS Yearly Net Income VS EBIT VS OCF VS FCFRCUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

1.2 Ratios

RCUS's Return On Assets of -21.57% is fine compared to the rest of the industry. RCUS outperforms 76.20% of its industry peers.
With a decent Return On Equity value of -47.79%, RCUS is doing good in the industry, outperforming 66.96% of the companies in the same industry.
Industry RankSector Rank
ROA -21.57%
ROE -47.79%
ROIC N/A
ROA(3y)-14.86%
ROA(5y)-20.44%
ROE(3y)-33.6%
ROE(5y)-35.4%
ROIC(3y)N/A
ROIC(5y)N/A
RCUS Yearly ROA, ROE, ROICRCUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCUS Yearly Profit, Operating, Gross MarginsRCUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RCUS has more shares outstanding
The number of shares outstanding for RCUS has been increased compared to 5 years ago.
RCUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RCUS Yearly Shares OutstandingRCUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
RCUS Yearly Total Debt VS Total AssetsRCUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 0.00, we must say that RCUS is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.00, RCUS is doing good in the industry, outperforming 63.23% of the companies in the same industry.
RCUS has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.08, RCUS is doing worse than 65.72% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 0
ROIC/WACCN/A
WACC9.44%
RCUS Yearly LT Debt VS Equity VS FCFRCUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M 800M

2.3 Liquidity

RCUS has a Current Ratio of 5.24. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
RCUS's Current ratio of 5.24 is in line compared to the rest of the industry. RCUS outperforms 55.42% of its industry peers.
RCUS has a Quick Ratio of 5.24. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
RCUS has a Quick ratio (5.24) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.24
Quick Ratio 5.24
RCUS Yearly Current Assets VS Current LiabilitesRCUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.25% over the past year.
Looking at the last year, RCUS shows a very strong growth in Revenue. The Revenue has grown by 119.72%.
Measured over the past years, RCUS shows a very strong growth in Revenue. The Revenue has been growing by 69.35% on average per year.
EPS 1Y (TTM)21.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.38%
Revenue 1Y (TTM)119.72%
Revenue growth 3Y14.72%
Revenue growth 5Y69.35%
Sales Q2Q%50%

3.2 Future

RCUS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.92% yearly.
The Revenue is expected to grow by 41.15% on average over the next years. This is a very strong growth
EPS Next Y16.46%
EPS Next 2Y-8.85%
EPS Next 3Y-2.75%
EPS Next 5Y7.92%
Revenue Next Year129.3%
Revenue Next 2Y36.26%
Revenue Next 3Y25.97%
Revenue Next 5Y41.15%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RCUS Yearly Revenue VS EstimatesRCUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
RCUS Yearly EPS VS EstimatesRCUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCUS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCUS Price Earnings VS Forward Price EarningsRCUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCUS Per share dataRCUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

RCUS's earnings are expected to decrease with -2.75% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.85%
EPS Next 3Y-2.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCUS BIOSCIENCES INC

NYSE:RCUS (2/21/2025, 8:04:00 PM)

After market: 11.2 +0.13 (+1.17%)

11.07

+0.33 (+3.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-25 2025-02-25/amc
Inst Owners94.92%
Inst Owner Change58.51%
Ins Owners6.49%
Ins Owner Change0.82%
Market Cap1.01B
Analysts81.05
Price Target33.66 (204.07%)
Short Float %11.48%
Short Ratio9.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.35%
Min EPS beat(2)7.78%
Max EPS beat(2)8.92%
EPS beat(4)3
Avg EPS beat(4)27.04%
Min EPS beat(4)-3.39%
Max EPS beat(4)94.85%
EPS beat(8)7
Avg EPS beat(8)19.54%
EPS beat(12)10
Avg EPS beat(12)62.86%
EPS beat(16)10
Avg EPS beat(16)43.48%
Revenue beat(2)2
Avg Revenue beat(2)37.29%
Min Revenue beat(2)25.3%
Max Revenue beat(2)49.28%
Revenue beat(4)4
Avg Revenue beat(4)100.38%
Min Revenue beat(4)7.14%
Max Revenue beat(4)319.8%
Revenue beat(8)6
Avg Revenue beat(8)56.29%
Revenue beat(12)9
Avg Revenue beat(12)106.15%
Revenue beat(16)10
Avg Revenue beat(16)77.36%
PT rev (1m)0%
PT rev (3m)5.35%
EPS NQ rev (1m)-1.26%
EPS NQ rev (3m)-5.29%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.85
P/FCF N/A
P/OCF N/A
P/B 1.79
P/tB 1.79
EV/EBITDA N/A
EPS(TTM)-3.15
EYN/A
EPS(NY)-4.92
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS2.87
BVpS6.17
TBVpS6.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.57%
ROE -47.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.86%
ROA(5y)-20.44%
ROE(3y)-33.6%
ROE(5y)-35.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 110%
Cap/Sales 4.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.24
Quick Ratio 5.24
Altman-Z 0
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)362.28%
Cap/Depr(5y)247.92%
Cap/Sales(3y)10.9%
Cap/Sales(5y)9.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.38%
EPS Next Y16.46%
EPS Next 2Y-8.85%
EPS Next 3Y-2.75%
EPS Next 5Y7.92%
Revenue 1Y (TTM)119.72%
Revenue growth 3Y14.72%
Revenue growth 5Y69.35%
Sales Q2Q%50%
Revenue Next Year129.3%
Revenue Next 2Y36.26%
Revenue Next 3Y25.97%
Revenue Next 5Y41.15%
EBIT growth 1Y7.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.09%
EBIT Next 3Y-11.42%
EBIT Next 5YN/A
FCF growth 1Y-139.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-135.46%
OCF growth 3YN/A
OCF growth 5YN/A